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Abstract
Objectives
Deficiencies of vitamin B12 and folate are associated with delayed development and neuro-
logical manifestations. The objective of this study was to measure the effect of daily supple-
mentation of vitamin B12 and/or folic acid on development in young North Indian children.
Methods
In a randomized, double blind trial, children aged six to 30 months, received supplement
with placebo or vitamin B12 and/or folic acid for six months. Children were allocated in a
1:1:1:1 ratio in a factorial design and in blocks of 16. We measured development in 422 chil-
dren by the Ages and Stages Questionnaire 3rd ed. at the end of the intervention.
Results
Compared to placebo, children who received both vitamin B12 and folic acid had 0.45 (95%
CI 0.19, 0.73) and 0.28 (95% CI 0.02, 0.54) higher SD-units in the domains of gross motor
and problem solving functioning, respectively. The effect was highest in susceptible sub-
groups consisting of stunted children, those with high plasma homocysteine (> 10 μmol/L)
or in those who were younger than 24 at end study. With the exception of a significant
improvement on gross motor scores by vitamin B12 alone, supplementation of either vita-
min alone had no effect on any of the outcomes.
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Conclusion
Our findings suggest that supplementation of vitamin B12 and folic acid benefit develop-
ment in North Indian Children.
Trial Registration
ClinicalTrials.gov NCT00717730
Introduction
Poor vitamin B12 status is common among young children in many low- to middle-income
countries (LMIC) [1–5]. Deficiency in vitamin B12 has been associated with decreased cogni-
tive performance among elderly [6], and case studies in infants show that severe vitamin B12
deficiency can dramatically affect the developing brain [3, 7]. Observational studies in children
have reported associations between vitamin B12 deficiency and neurodevelopment [8–10]. For
instance, in a cohort study in North Indian children, marginal vitamin B12 status was associ-
ated with lower scores on the mental development index of the Bayley Scales of Infant and
Toddler Development (Bayley) 2nd ed. [9]. Moreover, six weeks old Norwegian infants with
evidence of poor vitamin B12 status had substantially improved motor development one
month after a vitamin B12 injection [11].
Poor folate status may also occur in some populations in LMIC, including India [1, 4]. The
biochemical and metabolic effects of vitamin B12 and folate are closely related. Deficiency of
either vitamin results in elevation of plasma total homocysteine (tHcy) [12, 13], and the conse-
quences for neurodevelopment are similar [10]. In addition to the co-occurrence and possible
synergistic effects of micronutrients on development, several relevant factors such as growth,
infections and early life psychosocial factors are associated with developmental status in chil-
dren [14]. Hence randomized placebo-controlled trials (RCT) are called for to clarify the effect
of vitamin B12 and/or folate deficiency on early child development [10].
The objective of the current study was to measure the effect of two recommended daily
allowances of vitamin B12 and/or folic acid for six months on neurodevelopment. In a RCT in
young North Indian children, we compared scores of the different developmental domains of
the Ages and Stages Questionnaire 3rd. ed. (ASQ-3) (communication, gross motor, fine motor,
problem-solving and personal social) between a placebo group and three intervention groups
receiving vitamin B12 and/or folic acid for six months.
Materials and Methods
Participants and study setting
The children (n = 422) included in this study participated in a RCT (n = 1000) on the effect of
vitamin B12 and/or folic acid supplementation on childhood infections and growth in New
Delhi, India [15]. The trial was first registered at www.clinicaltrials.gov as NCT00717730 in
July, 2008, and at www.ctri.nic.in as CTRI/2010/091/001090 in August, 2010. The authors con-
firm that all ongoing and related trials for this intervention are registered.
The study children aged six to 30 months were recruited from low to middle socioeconomic
class families living in the Tigri and Dakshinpuri area in New Delhi with a total population of
about 300,000, and randomized in blocks of 16. The last 440 enrollments were requested to
participate in this developmental assessment sub study. Enrollment was from November 2010
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to March 2011, and the developmental assessment was conducted fromMay through Septem-
ber 2011. The study was approved by the ethics committees of the Society for Essential Health
Action and Training (India), Society for Applied Studies (India), Christian Medical College,
Vellore (India), and the Norwegian Regional Committee for Medical and Health Research Eth-
ics (REK VEST), July 2008.
Enrollment and randomization
A door-to-door survey was conducted to identify eligible children in all households in the area.
A physician and field supervisors screened the children for ongoing illnesses and measured the
hemoglobin levels. Cases of anemia were treated with oral iron as per national guidelines.
Availability of informed consent and no plans to move away over the next six months were
considered for enrollment. We excluded children with severe acute malnutrition (weight-for-
height z-scores< -3), and severe anemia (hemoglobin<7 g/dL), and they were referred for
treatment according to national guidelines. Children already using folic acid and/or vitamin
B12 supplements were not included in the study. We also excluded children that participated
in other trials and children with illnesses requiring hospitalization. With no screening of devel-
opmental delays prior to enrollment, only children with known developmental disabilities were
excluded. Only one child from each household was recruited for the study. Written informed
consent was obtained prior to enrollment from the caregiver on behalf of the children. In case
of non-literates, an impartial witness witnessed the consent. All witnesses were registered in a
list. The ethics committees approved the consent procedure. Demographic information was
collected at enrollment.
Using a factorial design, children were randomized in a 1:1:1:1 ratio in blocks of 16 to one of
four treatment groups: placebo, vitamin B12 only, folic acid only, and vitamin B12 and folic
acid (in the following, referred to as vitamin B12/folic acid). The randomization was stratified
into infants (<12 months) and older children ( 12 months) by assigning blocks to either of
these two strata. The vehicle for the vitamins and the placebo, was a lipid-based paste provided
in jars pre-labeled by the producer with a subject identification number and no indication on
study group. A scientist at the University of Bergen, who was otherwise not involved in the
study, provided the randomization list using Stata Version 10 (StataCorp, College Station, TX,
USA) linking the unique child identification number with the intervention group. The subject
identification number was the only indication that could link the paste to the study group.
Ensuring double blinding, the placebo and the vitamin supplements were identical in appear-
ance and taste and the allocation was masked to the participants as well as the study team
throughout the data collection period.
Inclusion and exclusion criteria, as well as the other study procedures were the same for the
main study and the current sub study.
Interventions
We have previously demonstrated that gastrointestinal illnesses as well as folate and vitamin
B12 deficiency is common in this population [4, 16, 17]. We therefore decided to provide folic
acid and vitamin B12 at doses that were approximately twice the recommended daily allow-
ances. The lipid based paste was chosen because of its acceptability in similar populations and
because it is a feasible way to provide vitamins and minerals to child populations without deg-
radation or contamination. The paste was prepared by NUTRISET, Ltd (Malaunay France).
The interventions were given to the enrolled children daily by field workers. On Sundays and
on public holidays the caregivers administered the supplementation to the children according
to instructions. When families were travelling, field workers provided the supplement for the
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planned travel period in smaller units. All children across study groups were supplemented
with one spoon (5 g) if they were 6 to 11 months, and two spoons (10 g) if they were 12 months
and above. Each 10 g of supplement contained 54.1 kcal total energy, 0.7 g proteins and 3.3 g
fat. For the intervention groups folic acid only, vitamin B12 only or vitamin B12/folic acid, the
10 g supplement also contained 150 μg folic acid or 1.8 μg vitamin B12 (as cyanocobalamin), or
the combination of both. For the younger children, the 5 g supplement contained half of the
vitamin doses of the older children. All children received the intervention for six months.
Developmental assessment
Development was assessed at the end of the study following six months supplementation. The
timing of the assessments was identical for all children in the sub study. Development was
assessed using the ASQ-3, a developmental screening tool constructed in the US [18]. The
ASQ-2nd ed. has been validated against a developmental assessment tool in North India, and
found to have good test characteristics for detecting developmental delay in this setting [19].
The ASQ-2 has also been used as an outcome measure in epidemiological studies worldwide
[20–22], where both continuous and dichotomous outcomes (cut-offs) have been reported.
The ASQ-3 consists of age-appropriate questionnaires, all containing 30 items divided into
five subscales: Communication, Gross motor, Fine motor, Problem-solving and Personal-
social, summing up to five subscale scores (range 0 to 60) and a total score (range 0 to 300).
Eleven forms (for age 12–36 months) were translated to Hindi following official recommenda-
tions [23], and items not suited for the cultural setting were identified and slightly adjusted
[24]. In the translated ASQ-3 version, the standardized alphas for the total ASQ-3 scores were
strong, indicating an overall acceptable internal consistency [24].
Three field supervisors were trained to administer the ASQ-3 directly with the child at the
research clinic in presence of caregivers [25]. The examiners elicited the relevant skills from the
child during sessions using standardized materials. The caregiver served as an important con-
tributor in supporting the child, eliciting behaviors and gave relevant information of the child’s
development when necessary. The three field supervisors were trained by the first author, a
clinical child psychologist with experience in training and the assessment of infants and young
children. During the 11 days of training, the field supervisors were standardized in performing
the procedure, and they reached a high inter-observer agreement both during training and in a
separate quality control where 10% of the observations were done in duplicate throughout the
study [24].
To assess the caregiver`s promotion of child development we carefully selected two ques-
tions from the standardized assessment tool Home Observation for Measurement of the Envi-
ronment (HOME) [26] that were asked the caregivers during the session. One question was on
“Mother`s belief that child`s behavior can be modified” and one was on “Mother`s encourage-
ment of developmental advances”.
Growth and biochemical markers
Trained field supervisors measured weight and length at baseline and after six months of sup-
plementation. Weight was measured to the nearest 50 g using Digitron scales. Length was mea-
sured using locally manufactured infantometers reading to the nearest 0.1 cm.
Venous blood samples were obtained at baseline for all children, and at end study in a sub-
sample of randomly selected blocks (94 children for the subsample). Three mL of blood was
collected into an evacuated tube containing EDTA (BD, Franklin Lakes, NJ, USA). Immedi-
ately following blood sampling, plasma was separated from the blood cells by centrifugation at
room temperature (450 x g x 10 min), transferred into storage vials and stored at -20 0C until
Vitamin B12 and Folic Acid on Child Development
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analysis. Plasma tHcy was analyzed using commercial kits (Abbott Park, IL, USA) [27]. Plasma
concentrations of vitamin B12 and folate were determined by microbiological assays using a
chloramphenicol-resistant strain of Lactobacillus casei and colistin sulfate-resistant strain of
Lactobacillus leichmannii, respectively [28].
Power calculations
We included the last 422 enrollments in this sub-study. The power to detect a standardized
mean difference (based on a t-test) of 0.4 (i.e. 20 points in total ASQ-3 scores) and 0.5 (25
points in total ASQ-3 scores) between the placebo and any of the treatment groups was 83 and
95 per cent, respectively. In these calculations, which were done by the “power” command in
Stata, we used a two-sided alpha error of 0.05.
Statistics and data management
The data was entered twice by two data entry clerks followed by validiation by a computer
manager. A total of 0.21% of the ASQ-3 responses were missing. For missing items an adjusted
total score was computed by dividing the total subscale score by the number of completed
items in the scale [29]. This number was then added depending on the amount of items miss-
ing. Height-for-age, weight-for-age and weight-for-height z scores were calculated using the
most recent WHO growth charts [30]. The ASQ-3 scores for the total sample are presented as
means (SD). We used linear regression to compare the intervention groups: vitamin B12, folic
acid and vitamin B12/folic acid against the placebo on a continuous scale. We also used multi-
ple logistic regression on the total and subscale ASQ-3 scores categorized on the 25th percen-
tile. In these models, we also examined the effects in various predefined subgroups based on
the following baseline characteristics (cut-offs in brackets): age (<12 months), stunting (< -2 z
scores height/length-for-age), wasting (< -2 z scores weight-for-height/length), being under-
weight (< -2 z scores weight-for-age), low plasma vitamin B12 (<200 pmol/L), low plasma
folate (<7.5 nmol/L), and high plasma tHcy (>10 μmol/L). This is the same approach for pre-
senting main and subgroup effects as we used when presenting the effect of the interventions
on the incidence of infections [15]. For the subgroup models, we adjusted for sex, age, breast-
feeding status, height-for-age z-scores and mother´s encouragement of developmental
advances. Post hoc, we examined the effect in an additional subgroup: 24 months vs.> 24
months at end study (corresponding to18 months vs.>18 months at enrollment). We also
performed the overall analyses adjusting for important baseline factors such as sex, gender,
breastfeeding status, height-for-age, weight-for-age z-scores and log transformed family
income. We included interaction terms in the models to measure whether the effects between
the subgroups were significantly different. In these models, we also measured the interaction
between folic acid and vitamin B12 supplementation. We calculated standardized mean differ-
ences by dividing the mean differences by the overall SDs of the different outcomes. Statistical
analyses were performed in Stata, version 13 (Stata corporation, College Station, TX). All anal-
yses were done following an intention-to-treat protocol. P< 0.05 (two-tailed) was considered
significant.
Results
Fig 1 shows the flow of the participants through the study. Among the 1000 children random-
ized into the main study, the last 440 enrollments were included for developmental assessment.
Three children were not available for assessment and 15 did not wish to participate, hence the
final number of participants was 422. Baseline characteristics for the children in the four inter-
vention groups are presented in Table 1. As reported from the main study, adherence was
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excellent and 96% of the scheduled doses were ingested [15]. Furthermore, compared to the
placebo group, plasma vitamin B12 concentrations increased substantially in the group of chil-
dren that received vitamin B12 alone or in combination with folic acid. Likewise, plasma folate
levels increased significantly in children who received folic acid alone or in combination with
vitamin B12 (Table 2).
The effect of the intervention on development
Overall, the total ASQ-3 score was 12.6 (95% CI -1.1, 26.3) (P = 0.071) points higher in the
group of children who received six months of vitamin B12/folic acid supplementation com-
pared to those who received placebo (Table 3). Higher scores in the vitamin B12/folic acid sup-
plementation group were also observed for the Gross motor subscale (P = 0.001) and the
Problem-solving subscale (P = 0.048), while no significant effect was observed for the Commu-
nication, Fine motor and Personal social subscales (Table 3). The mean standardized effect
sizes for the Total, Gross Motor and the Problem-solving subscales were 0.25 (95% CI -0.02,
0.53), 0.46 (95% CI 0.19, 0.73) and 0.28 (95% CI 0.02, 0.54) SD units respectively.
In groups that either received folic acid or vitamin B12 alone, we did not find significant dif-
ferences from placebo with the exception of children who received vitamin B12 without folic
acid: The gross motor scale was 4.0 (95% CI 0.3, 7.8) points higher in the vitamin B12 group
Fig 1. Trial profile of a randomized, placebo controlled trial on the effect of vitamin B12 and/or folic acid administration on development in 6–30
months old North Indian children.
doi:10.1371/journal.pone.0129915.g001
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than in the placebo group (Table 3). The corresponding effect size was 0.29 (95% CI 0.02, 0.55)
SD units.
We repeated the analyses using logistic regression after dichotomizing the outcomes at the
25 percentiles. Similar results were observed as for the linear regression reported above
(Table 4). We also undertook these comparisons adjusting for baseline differences; the adjusted
analyses resulted in only modest changes to the estimates and the levels of significance (S1 and
S2 Tables).
Table 1. Baseline characteristics of the 422 children age 6–30months.
Placebo (n = 105) Vitamin B12 (n = 109) Folic Acid (n = 107) Vitamin B12 & Folic Acid (n = 101)
Child characteristics
Age, months 16.2 ± 7.41 15.3 ± 6.6 15.8 ± 7.6 15.2 ± 6.6
6 − 11 months, n (%) 36 (36.2) 34 (31.2) 35 (32.7) 34 (33.7)
12 − 30 months, n (%) 69 (63.8) 75 (68.8) 72 (67.3) 67 (66.3)
Boys, n (%) 62 (59.0) 52 (47.7) 51 (47.7) 51(50.5)
Still breastfed, n (%) 92 (87.6) 97 (89.0) 88 (82.2) 87 (87.0)2
Z scores:
Weight-for-height (WHZ) -1.0 ± 0.9 -0.8 ± 0.9 -0.7 ± 1.0 -0.8 ± 0.9
Height-for-age (HAZ) -1.9 ± 1.2 -1.7 ± 1.2 -1.7 ± 1.2 -1.7 ± 1.0
Weight-for-age (WAZ) -1.7 ± 1.0 -1.5 ± 1.0 -1.4 ± 1.1 -1.4 ± 0.9
Wasted (<-2 WHZ), n (%) 15 (14.3) 12 (11.0) 8 (7.5) 7 (6.9)
Stunted (<-2 HAZ), n (%) 47 (44.8) 45 (41.3) 43 (40.2) 34 (33.6)
Underweight (<-2 WAZ), n (%) 42 (40.0) 28 (25.7) 36 (33.6) 25 (24.8)
Family characteristics
Annual family income (INRx1000)3 72 (48, 120) 82 (60, 120) 72 (60, 126) 84 (62, 140)
Has television, scooter or cooler, n (%) 90 (85.7) 98 (89.9) 98 (91.6) 91 (90.1)
Living in joint family, n (%) 45 (42.9) 44 (40.4) 54 (50.5) 51 (50.5)
Family size 5.8 ± 2.4 5.8 ± 2.9 5.8 ± 2.4 5.9 ± 2.4
Age of mother, years 25.8 ± 4.6 26.5 ± 8.2 25.0 ± 3.6 25.3 ± 3.9
Mothers years of schooling n (%)
No schooling (>5) 22 (21) 30 (27.5) 24 (22.4) 22 (21.8)
Primary (5 years complete) 65 (61.9) 50 (45.9) 46 (43) 48 (47.5)
Middle (10 years complete) 6 (5.7) 13 (11.9) 9 (8.4) 11 (10.9)
Higher (>10 years) 12 (11.4) 16 (14.7) 28 (26.2) 20 (19.8)
Fathers years of schooling
No schooling (>5) 16 (15.2) 13 (11.9) 13 (12.2) 11 (10.9)
Primary (5 years complete) 36 (34.3) 36 (33.1) 41 (38.3) 39 (38.6)
Middle (10 years complete) 26 (24.8) 37 (33.9) 23 (21.5) 27 (26.7)
Higher (>10 years) 27 (25.7) 23 (21.1) 30 (28) 24 (23.8)
Mothers who work, n (%) 6 (5.7) 9 (8.3) 8 (7.5) 3 (2.7)
Attending Anganwadi centre4, n (%) 6 (5.8) 13 (11.9) 12 (11.2) 9 (8.9)
Folate and vitamin B12 status at baseline
Vitamin B12 < 200 pmol/L, n (%) 36 (34.3) 36 (33.0) 39 (36.5) 27 (26.7)
Folate < 7.5 nmol/L, n (%) 27 (25.7) 38 (34.8) 30 (28.0) 36 (35.6)
tHcy > 10 μmol/L, n (%) 67 (63.5) 60 (53.21) 62 (57.9) 58 (57.4)
1 Mean±SD all such values.
2 Missing information from 1 child.
3 Indian Rupees in median (Interquartile range).
4Childcare centre.
doi:10.1371/journal.pone.0129915.t001
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Subgroup analyses
In the subgroup analyses we present the results from the logistic regression analyses. Stunted
children that received six months of vitamin B12/folic acid supplementation had substantially
and significantly reduced odds [Odds ratio (OR): 0.26 (95% CI 0.09, 0.78) (P = 0.016)] of being
in the lowest quartile of the ASQ-3 score. This was also the case for children with elevated levels
Table 2. Concentrations of markers of vitamin B12 and folate status and change compared to the placebo.
Placebo (n = 105) B12 (n = 109) Folic acid (n = 107) B12 & Folic acid
(n = 101)
Baseline Median IQR1 Median IQR Median IQR Median IQR
Plasma vitamin B12 (pmol/L) 260 (170–353) 269 (178–
419)
286 (180–473) 307.0 (198–439)
Plasma folate (nmol/L) 10.4 (7.0–18.4) 9.1 (6.1–
18.2)
11.8 (6.7–20.3) 9.7 (6.1–17.8)
Plasma tHcy (μmol/L) 12.7 (9.1–17.2) 10.6 (8.7–
15.0)
11.8 (8.7–15.2) 10.4 (8.2–13.5)
End of study (n = 24) (n = 22) (n = 24) (n = 24)
Plasma vitamin B12 (pmol/L) 285 (199–368) 362 (271–
708)
297 (225–405) 446 (302–565)
Plasma folate (nmol/L) 16.6 (11.9–
22.5)
11.8 (8.0–
19.3)
49.0 (28.6–
64.0)
50.5 (31.2–
78.4)
Plasma tHcy (μmol/L) 12.4 (10.3–
15.5)
8.0 (6.5–9.5) 8.1 (6.7–11.7) 7.6 (5.8–10.0)
Change from baseline to end of study compared
to placebo
Mean
diff.2
95% CI 3 Mean
diff.
95% CI Mean
diff.
95% CI
Vitamin B12 (pnmol/L) 0 118 (17, 219) 6 (-93, 105) 102 (4, 202)
Folate (nmol/L) 0 -3.2 (-15.0,
8.6)
28.5 (17.0,
40.0)
34.3 (22.8,
45.7)
tHcy (μmol/L) 0 -1.7 (-5.0, 1.5) -1.2 (-4.5, 2.1) -5.3 (-8.6, -2.1)
1 Interquartile range.
2 Mean difference change in concentration from baseline.
3 95% Confidence interval.
doi:10.1371/journal.pone.0129915.t002
Table 3. The effect of vitamin B12 and/or Folic acid on ASQ-3 total and subscale scores.
Placebo (n = 105) B12 (n = 109) Folic acid (n = 107) B12 & Folic acid (n = 101)
Mean (SD) Mean (SD) Mean Diff.1 95%CI2 Mean (SD) Mean Diff. 95%CI Mean (SD) Mean Diff. 95%CI
Total ASQ-3 228.0 ± 47.2 230.6 ± 52.2 2.6 (-10.8, 16.0) 228.6 ± 55.8 0.6 (-12.7, 14.3) 240.6 ± 43.2 12.6 (-1.1, 26.3)
Subscale
Communication 47.4 ± 14.8 47.8 ± 15.9 0.4 (-2.8, 4.6) 48.2 ± 15.7 0.8 (-3.4, 5.0) 47.9 ± 15.4 0.5 (-3.8, 4.7)
Gross motor 42.8 ± 15.2 46.8± 13.6 4.0 (0.3, 7.8)* 45.8 ± 15.3 3.0 (-0.8, 6.8) 49.3 ± 11.4 6.5 (2.7, 10.3)**
Fine motor 47.6 ± 13.2 47.1 ± 13.3 -0.5 (-4.1, 3.1) 44.5 ± 14–9 -3.1 (-6.8, 0.5) 47.6 ± 12.2 0 (-3.7, 3.7)
Problem-solving 44.3 ± 14.1 43.1 ± 15.6 -1.2 (-4.9, 2.5) 43.9 ± 13.3 -0.4 (-4.1, 3.3) 48.1 ± 11.5 3.8 (0.0, 7.6)*
Personal social 45.9 ± 12.4 45.7 ± 12.5 -0.2 (-3.5, 3.2) 46.4 ± 12.9 0.5 (-2.8, 3.9) 47.7 ± 12.0 -1.8 (-1.6, 5.2)
*p<0.05.
**p<0.01.
1 Mean difference in total ASQ scores from Placebo.
2 95% Confidence interval.
doi:10.1371/journal.pone.0129915.t003
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of tHcy at baseline with significantly reduced odds [OR: 0.38 (95% CI 0.16, 0.92) (P = 0.032)]
of being in the lowest quartile. Based on the assumption that the period up to 24 months is a
critical time for brain development, we also measured the effect of the interventions separately
for children who were24 months at end study vs. the older children. In children24 months
at the end of the study ( 18 months at enrollment), vitamin B12/folic acid supplementation
led to significantly lower odds of being in the lower quartile of the ASQ-3 score (OR: 0.37, 95%
CI 0.17–0.83, P = 0.015). These effects were not seen in children aged 19 to 30 months at
enrollment (Table 5). None of the subgrouping variables significantly modified the effect of
the interventions on the ASQ-3 scores, and the interaction between folic acid and vitamin B12
supplementation was not significant.
Discussion
In our study, we found a borderline significant positive effect of receiving vitamin B12 and folic
acid for six months on the total ASQ-3 scores. We also found a significant and positive effect of
vitamin B12 and folic acid in the developmental domains of gross motor functioning and prob-
lem-solving skills. The effects of supplementation were most evident in children who were
stunted, and in children who had high plasma tHcy consistent with poor folate and/or vitamin
B12 status, and in children who completed the study before their 2nd birthday [31]. Except for
vitamin B12 in relation to gross motor functioning, there was no significant benefit of giving
vitamin B12 or folic acid alone on early child development.
North Indians, including children, often have poor vitamin B12 status due to dietary prac-
tices (vegetarianism) and poverty [2]. Poor vitamin B12 status was also seen in the present
study. In addition, a large proportion had low plasma folate, and nearly 60% of these young
children had elevated tHcy at baseline. Children who received supplementation of vitamin B12
and folic acid for six months had substantial improvement in vitamin status and a reduction in
plasma tHcy concentrations [15].
Through our assessment across developmental domains, we found that children who
received supplementation of vitamin B12 and folic acid for six months had improved gross
motor outcomes and problem-solving skills, while there were no significant changes in the
domains of communication, fine motor and personal-social skills. The results are in line with
previous observational studies that have documented an association between vitamin B12
Table 4. ORs1 (95%CIs2) for being in the lower quartile of ASQ-3 total and subscale scores compared with placebo.
Placebo (n = 105) B12 (n = 109) Folic acid (n = 107) B12 & Folic acid (n = 101)
OR OR 95% CI OR 95% CI OR 95% CI
Total ASQ-3 1 0.66 (0.37, 1.19) 0.75 (0.42, 1.34) 0.53 (0.29, 0.99)*
Subscale
Communication 1 0.95 (0.53, 1.68) 0.89 (0.50, 1.59) 0.88 (0.49, 1.59)
Gross motor 1 0.74 (0.43, 1.28) 0.74 (0.43, 1.28) 0.39 (0.22, 0.71)**
Fine motor 1 0.99 (0.56, 1.74) 1.57 (0.90, 2.73) 0.93 (0.52, 1.66)
Problem-solving 1 0.97 (0.57, 1.67) 0.83 (0.48, 1.43) 0.52 (0.29, 0.93)*
Personal social 1 0.98 (0.56, 1.71) 1.05 (0.60, 1.83) 0.72 (0.40, 1.28)
*p<0.05.
**p<0.01.
1 Odds Ratio.
2 95% Confidence interval.
doi:10.1371/journal.pone.0129915.t004
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status and aspects of development [9, 32]. However, the specific developmental domains that
are related to vitamin B12 differ between studies and are not directly comparable due to meth-
odological differences. For example, in the study in North Indian children, marginal vitamin
B12 status was related to lower scores on the mental development index of the Bayley 2nd ed,
but not to the scores on the psychomotor scale [9]. These scales are not directly comparable to
the ASQ domains. The association between gross motor functioning and vitamin B12 has
been documented across several studies, i.e. in a Dutch vegan study group, where vitamin B12
deficient infants suffered from slower gross motor and language development compared to
non-deficient infants [32]. Further, in a recently published RCT, Norwegian infants with poor
vitamin B12 status and who were referred to a pediatrician due to feeding problems had sub-
stantially and significantly improved feeding and gross motor functioning following a vitamin
B12 injection [11]. These findings are consistent with the findings in the present study. How-
ever, in the study of Norwegian children, they did not assess other developmental domains.
Furthermore, while the Norwegian study relates to the rare situation of a child being submitted
to hospital for feeding problems, our data relate to associations of the general Indian popula-
tion of people belonging to middle to poor socioeconomic classes.
Given the nature of the developing brain with periods of regional brain growth spurts and
rapid maturation, it is challenging to compare results on specific developmental areas across
age groups. Functions under development are particularly sensitive to influences, which may
Table 5. ORs1 (95%CIs)2 for being in the lower quartile of ASQ-3 total in the intervention group compared with placebo in subgroups.3
Placebo Vitamin B12 Folic acid B12 & Folic acid
N OR OR 95% CI OR 95% CI OR 95% CI
Subgroups
Age in months at baseline
6 to11 months 138 1 0.51 (0.17, 1.50) 0.79 (0.26, 2.39) 0.48 (0.16, 1.48)
12 to 30 months 283 1 0.74 (0.33, 1.63) 1.12 (0.50, 2.48) 0.59 (0.25, 1.36)
6 to 18 months 149 1 0.46 (0.22–0.99)* 0.73 (0.34–1.57) 0.37 (0.17–0.83)*
19 to 30 months 273 1 1.65 (0.49–5.60) 1.87 (0.55–6.33) 1.20 (0.33–4.43)
Growth at baseline
Wasted 42 1 0.57 (0.06, 5.25) 4.29 (0.29, 62.61) 1.34 (0.11, 16.38)
Not wasted 379 1 0.67 (0.34, 1.32) 0.92 (0.47, 1.78) 0.53 (0.26, 1.08)
Stunted 169 1 0.48 (0.19, 1.22) 0.77 (0.29, 2.02) 0.26 (0.09, 0.78)*
Not stunted 252 1 0.95 (0.39, 2.34) 1.25 (0.51, 3.08) 1.11 (0.46, 2.71)
Underweight 131 1 0.54 (0.17, 1.64) 0.84 (0.29, 2.45) 0.64 (0.21, 1.97)
Not underweight 290 1 0.78 (0.36, 1.72) 1.05 (0.47, 2.35) 0.49 (0.21, 1.18)
Biochemical markers at baseline
Vitamin B12 <200 pmol/L 137 1 0.48 (0.17, 1.38) 0.68 (0.24, 1.90) 0.61 (0.20, 1.85)
Vitamin B12 200 pmol/L 284 1 0.87 (0.39, 1.95) 1.15 (0.51, 2.65) 0.59 (0.25, 1.38)
Folate <7.5 nmol/L 131 1 0.95 (0.28, 3.28) 1.44 (0.41, 5.13) 0.58 (0.16, 2.11)
Folate 7.5 nmol/L 290 1 0.65 (0.30, 1.38) 0.84 (0.40, 1.76) 0.60 (0.27, 1.32)
tHcy >10 μmol/L 247 1 0.66 (0.30, 1.46) 0.73 (0.33, 1.61) 0.38 (0.16, 0.92)*
tHcy 10 μmol/L 174 1 1.10 (0.37, 3.29) 1.86 (0.61, 5.67) 1.10 (0.37–3.27)
*p<0.05.
1Odds Ratio.
295% Confidence interval.
3Adjusted for sex, age, breastfeeding status, stunting and Mother`s encouragement of developmental advances (dichotomus).
doi:10.1371/journal.pone.0129915.t005
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give rise to developmentally dependent outcomes [33, 34]. Consequently, we need to consider
the timing of the exposure as well as the period of assessment [34, 35]. For instance, in the
Dutch study of vegan families, findings indicate long-term consequences of early vitamin B12
deficiency on cognitive performance in adolescence [8]. In early childhood, these adolescents
had significantly lower functioning in the areas of gross motor and language development com-
pared to a control group [32]. In our study, we measured the short-term effects following six
months supplementation. The time required for improvements to be detectable in the develop-
ing brain and possible to assess, may be domain specific [36]. Thus, although we did not find
significant effects on communication skills, fine motor functioning and personal social abilities,
an impact on these domains may require longer exposure time, or improvements may become
apparent later in life. The interruption of myelination has been suggested as a possible mecha-
nism linking vitamin B12 deficiency and adverse neurodevelopment [7]. Myelination facilitates
communication in the brain and interruptions may influence the speed of conductance and
thus the process of learning and acquisition of skills. Our result may indicate that the mecha-
nisms of improved myelination give a more rapid effect in gross motor and problem-solving
skills than for the other domains assessed. On the other hand, it has been argued that myelin
repair is a slow process, and the improvements observed after short-term vitamin B12 supple-
ment may be related to other effects such as increased energy-production in the central nervous
system [37]. Thus, the improvements in the current study may be due to increased energy and
attention, which are important factors for the performance both for gross motor abilities and
problem-solving skills. Further research is required to achieve a deeper understanding of the
specific consequences of vitamin B12 and folate deficiency on the developing brain.
Being a time of rapid growth, the period from gestation to 24 months of age is a sensitive
period for brain development in which the brain is particularly susceptible to various exposures
[33, 35, 38]. In support of this, there was a significant benefit of the vitamin B12 and folic acid
supplementation in children who were 18 months at the start of supplementation and
received all supplementation before they reach 24 months of age. Thus, our findings support
that the timing of nutritional influence is of significance for the outcome of neurodevelopment.
The effect of vitamin B12 and folic acid supplementation on total ASQ-3 scores was most
apparent in stunted children and in children with elevated tHcy. Childhood stunting is a proxy
for several factors that are associated with poor neurodevelopment [39], consequently there
might be a large potential for improvements among children who are stunted. The hypothesis
of “functional isolation” where a malnourished child fails to elicit appropriate care and stimula-
tion from the caregiver due to behavior symptoms such as irritability and apathy, may, in part,
explain the effect in this subgroup [40]. Stunting could also reflect poor long-term vitamin B12
or folate intake, and the improved scores in children receiving vitamin B12 and folic acid may
suggest that developmental delay in stunted children partly is related to low folate or vitamin
B12 status. This possibility is supported by the finding that children with elevated levels of
tHcy at baseline had a significant beneficial effect of vitamin B12 and folic acid supplementa-
tion on the total ASQ-3 score, while those with normal tHcy concentration did not. Stunting or
elevated tHcy did not significantly modify the effect of the intervention on the total ASQ-3
score, but it should be noted that the trial was not powered to measure such interactions.
Our results give support to the hypothesis of the importance of vitamin B12 and folate for
neurodevelopment and subsequent behavioral outcomes. Similarly, a recent report from the
current study provides evidence for the importance of vitamin B12 for growth showing that
poor vitamin B12 status in the children contributes to poor growth [41]. Clearly, there are sev-
eral modifiable risk factors associated with adverse neurodevelopment other than vitamin B12
and folate deficiency [14]. There is sound evidence that adequate stimulation and responsive
caregiving is crucial for healthy neurodevelopment as recently illustrated in a report from the
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current study [42]. Furthermore, biological risk factors such as childhood infections and
chronic undernutrition may lead to adverse neurodevelopment and unfulfilled developmental
potential [14]. Further research is needed to understand the role of vitamin B12 and folate as
one important factor for neurodevelopment in the complex interrelation between brain devel-
opment and environmental influences.
Strength and weaknesses
To our knowledge, this study is the first RCT that has measured the effects of vitamin B12 and/or
folic acid on child development. This is a well-conducted RCT with few losses to follow-up and
excellent adherence to the supplementation [15]. Despite an optimal randomization procedure
involving more than 400 children, there were some baseline differences in family characteristics
and physical growth between the groups. These represent a limitation to the study that may con-
found our effect estimates. We have repeated the analyses adjusting for these and other relevant
baseline characteristics such as sex, age, breastfeeding status, height-for age and weight-for-height
z-scores and log transformed family income. These adjustments resulted in minor alterations in
the effect estimates and, hence, the level of significance. However, the main finding of a beneficial
effect of vitamin B12/folic acid on gross motor and problem-solving skills remained significant
(S1 and S2 Tables). If we had measured development at baseline in addition to at end study, we
could have estimated the change in ASQ scores throughout the supplementation period and
thereby adjusted for baseline differences in the ASQ scores. This was not possible due to the timing
of the parent project and the time it took to prepare the instruments for the current sub-study.
Despite the fact that each study group consisted of more than 100 children and that we carefully
adjusted for baseline differences and other relevant variables, we cannot rule out residual con-
founding and our findings need to be confirmed before treatment recommendations can be made.
The ASQ-3 is a screening tool for the assessment of developmental delay constructed in the
US with binary cut-offs, but has been used to measure developmental status on a continuous
scale in several studies, as in the present study. It should be noted, that the questionnaires have
not yet been validated for this purpose. We translated 11 ASQ-3 forms to Hindi particularly
for this study, and the translated and adjusted ASQ-3 served as an easily administered and cost
efficient assessment tool [24]. However, alpha values indicated questionable internal consis-
tency in a few subscales and age categories. Poor internal consistency can be due to constant
items (lack of variability of the responses) or random errors. In a randomized trial, random
errors should be similar in the study groups and accordingly not result in biased effect esti-
mates. More comprehensive assessment tools, such as the Bayley scales, or tools for social emo-
tional functioning, could have added a broader picture of the children`s skills and abilities.
Finally, more advanced neuroimaging techniques might have identified unique changes to the
developing brain in early childhood.
Conclusion
In a RCT of supplementation with vitamin B12 and folic acid in six to 30 months old children we
found beneficial effects on neurodevelopment as assessed by a screening tool in the domains of
gross motor functioning and problem solving skills. These results need to be confirmed in other
populations with more comprehensive assessment tools, and further research is recommended
on the long-term effects of marginal vitamin B12 and folate status in the developing brain.
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